Terms: = Skin cancer AND TRRAP, TR-AP, 8295, ENSG00000196367, Q9Y4A5, PAF400, PAF350/400, FLJ10671, STAF40, Tra1 AND Clinical Outcome
9 results:
1. MAGE-A3 is a prognostic biomarker for poor clinical outcome in cutaneous squamous cell carcinoma with perineural invasion via modulation of cell proliferation.
Chen A; Santana AL; Doudican N; Roudiani N; Laursen K; Therrien JP; Lee J; Felsen D; Carucci JA
PLoS One; 2020; 15(11):e0241551. PubMed ID: 33227008
[TBL] [Abstract] [Full Text] [Related]
2. Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients.
Chang WT; Lu SN; Rau KM; Huang CS; Lee KT
Kaohsiung J Med Sci; 2018 Jul; 34(7):391-399. PubMed ID: 30063012
[TBL] [Abstract] [Full Text] [Related]
3. Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.
Kaneko S; Ikeda K; Matsuzaki Y; Furuse J; Minami H; Okayama Y; Sunaya T; Ito Y; Inuyama L; Okita K
J Gastroenterol; 2016 Oct; 51(10):1011-21. PubMed ID: 26931117
[TBL] [Abstract] [Full Text] [Related]
4. A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.
Lee JK; Capanu M; O'Reilly EM; Ma J; Chou JF; Shia J; Katz SS; Gansukh B; Reidy-Lagunes D; Segal NH; Yu KH; Chung KY; Saltz LB; Abou-Alfa GK
Br J Cancer; 2013 Aug; 109(4):915-9. PubMed ID: 23900219
[TBL] [Abstract] [Full Text] [Related]
5. Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial).
Degen A; Weichenthal M; Ugurel S; Trefzer U; Kilian K; Garbe C; Egberts F; Poppe LM; Hauschild A; Gutzmer R
J Dtsch Dermatol Ges; 2013 Sep; 11(9):846-53. PubMed ID: 23879405
[TBL] [Abstract] [Full Text] [Related]
6. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.
Van Cutsem E; Tejpar S; Vanbeckevoort D; Peeters M; Humblet Y; Gelderblom H; Vermorken JB; Viret F; Glimelius B; Gallerani E; Hendlisz A; Cats A; Moehler M; Sagaert X; Vlassak S; Schlichting M; Ciardiello F
J Clin Oncol; 2012 Aug; 30(23):2861-8. PubMed ID: 22753904
[TBL] [Abstract] [Full Text] [Related]
7. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction.
Wainberg ZA; Lin LS; DiCarlo B; Dao KM; Patel R; Park DJ; Wang HJ; Elashoff R; Ryba N; Hecht JR
Br J Cancer; 2011 Sep; 105(6):760-5. PubMed ID: 21811258
[TBL] [Abstract] [Full Text] [Related]
8. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
Harris KA; Weinberg V; Bok RA; Kakefuda M; Small EJ
J Urol; 2002 Aug; 168(2):542-5. PubMed ID: 12131305
[TBL] [Abstract] [Full Text] [Related]
9. The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b.
Tsavaris N; Baxevanis C; Kosmidis P; Papamichael M
Cancer Immunol Immunother; 1996 Oct; 43(2):94-102. PubMed ID: 8954143
[TBL] [Abstract] [Full Text] [Related]
